Medicine · Français

Will the CHMP issue an opinion on apitegromab in spinal muscular atrophy before 30 June 2027?

deadline 2027-06-30 confidence high tier 1 evidence
87%PolySignal estimate

Resolution criterion

Yes if the CHMP adopts an opinion, positive or negative, published in its meeting highlights, by 30 June 2027. A withdrawal of the application or the absence of an opinion count as no.

Verified starting state

The CHMP opinion is held up pending the FDA's classification of the Catalent Indiana fill-finish site, inspected in April 2026, or the addition of a second fill site to the MAA. Scholar Rock was targeting an opinion later in 2026. The blockage is industrial rather than scientific, on a timeline dependent on a third-party regulator. (20 July 2026)

What pushes it up

What pushes it down

What would move this number most

The timing of the FDA's re-classification of the Catalent Indiana site or the speed at which the EMA can validate an alternative manufacturing site.

How this number is built

Deadline2027-06-30
Base rate85%
Best evidencetier 1 · 2 article(s) used
Independent runs85 · 88 (spread 3 pts)
Confidencehigh
Evidence capnot triggered
Last revised2026-09-20 09:02
Modelgemini-3-flash-preview

Sources consulted

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2026tier 1 · EMA (actualités) · 2026-09-18Europe's CHMP endorses slew of new medicines, including new offerings from Novo and AZtier 3 · fiercepharma.com · 2026-09-18